Press Releases
Resilience Establishes Multi-Product Development and Manufacturing Collaboration with Takeda’s Plasma-Derived Therapies Business Unit
National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit.
As part of the agreement, Resilience will focus on supporting the development and manufacture...
Clinical Trials
Velocity Clinical Research makes tech investments to strengthen patient and client engagement in clinical trials
Velocity Clinical Research, the largest fully integrated clinical site organization, announces three key tech investments to expand its patient community, increase client engagement, and speed up drug development across all its 30 integrated locations.
In the past 12 months, Velocity...
Press Releases
PHARMINTECH and IPACK-IMA: a synergic union
The 7thedition of Pharmintech Exhibition is goingto take place in Milan from May 3 to 6, 2022 in conjunction with IPACK-IMA, the most important international trade fair in 2022 for processing and packaging solutions.
The two events will combine into...
Press Releases
Glenmark inks agreement with AstraZeneca to commercialize its product Pulmicort Respules in Colombia
Glenmark Pharmaceuticals, an innovation–driven, global pharmaceutical company, announced that its subsidiary Glenmark Pharmaceuticals Colombia S.A.S. and AstraZeneca Colombia S.A.S. have entered into an exclusive licensing agreement for the commercialization of AstraZeneca's drug Pulmicort Respules®. Under the terms of the...
Packaging & Labelling
Envirotainer introduces the RAP for the future – part of the Releye series
Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, launched its latest innovation, the Releye® RAP. This is complemented by the new Control Tower managed service.
The Releye® RAP sets a new benchmark for...
Press Releases
Lilly’s bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
The U.S. FDA has issued an Emergency Use Authorization for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company announced.
Bebtelovimab can now be used for the treatment of mild-to-moderate COVID-19 in adults and pediatric...
Press Releases
MaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France
MaaT Pharma , French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer and Skyepharma, a Contract Development and Manufacturing Organization (CDMO) specialized in formulating...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















